Furthermore, in leukaemias like chronic myeloid leukaemia (CML), effective treatment with imatinib leads to undetectable levels of BCR-ABL; however, recent evidence suggests that CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients [23]. Here, ABL1 is linked to leukemia.